A deep-dive for pharma IP teams, portfolio managers, and institutional investors on the strategies, IP valuations, and commercial mechanics that […]

The biopharma industry has spent decades optimizing for efficiency. Lean supply chains, single-source API relationships, centralized cell storage, and just-in-time

Own the Market After Your Patent Dies A technical deep dive for pharma IP teams, portfolio managers, R&D leads, and

Why Formulation Patents Are the Most Undervalued Asset in Pharma IP The pharmaceutical industry spent roughly $260 billion on R&D

For biopharma IP teams, portfolio managers, R&D leads, and institutional investors who track biologic patent cliffs for a living. 1.

Books and Research Papers Citing DrugPatentWatch All Years | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 2025 — 11 Books and Research Papers Citing DrugPatentWatch Gregory, A. (2025).

A playbook for IP teams, portfolio managers, and R&D leads — from Paragraph IV mechanics and biosimilar patent dance tactics

The business of generic drug development is often misunderstood as a simple exercise in duplication. For many years, we operated

How commercial manufacturing costs actually get built, what drives them, how CDMOs protect their pricing through IP assets, and what